Patient Resources

POMALYST® (pomalidomide), in combination with dexamethasone, is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.

What you need to know about the POMALYST REMS® program

Your doctor will enroll you in the POMALYST REMS® program so that you can receive your medication. Use the materials below to learn more about the POMALYST REMS® program, and what you need to do.

You can take your mandatory confidential patient survey at CelgeneRiskManagement.com in English or Spanish by clicking one of the buttons below.

You can also complete your survey by using the Celgene REMS mobile app for your iPad. Please download the app to your iPad by clicking here:



Attention Females Who Can Get Pregnant

Unless you abstain from sexual intercourse with a male partner, you are required to use at the same time at least 1 highly effective birth control method and at least 1 additional effective method every time you have sex with a male. Below, you will find a printable letter that you can bring with you to your next medical appointment that discusses your reproductive health. This will help you and your healthcare provider understand what types of birth control options are best for you.

For additional information about the POMALYST REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436

Download the
Celgene REMS mobile app
for CelgeneRiskManagement.com
to your iPad here: